A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy.

Trial Details

NCT ID
NCT06371274
Phase
NA
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • ATRA
  • Toripalimab
Locations (sample)
  • Hangzhou, Zhejiang Province, P.R. China, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥18 years at the time of signing the informed consent form;
  • Pathologically confirmed as triple-negative breast cancer based on recent biopsy or other pathological specimens, with histological and/or cytologi…
  • Patients with unresectable locally advanced or metastatic triple-negative breast cancer who have failed at least second-line standard treatment reg…
  • According to RECIST 1.1, at least one measurable lesion is required. Patients with only skin lesions or bone lesions are not eligible for inclusion;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →